Blood cancer care
Expert blood cancer care at Penn Medicine
Blood cancer, also called hematologic cancer, occurs when abnormal cells in the blood grow out of control. Hematology oncology experts at Penn Medicine have a long history of advancing the science of blood cancers like leukemia, lymphoma, and multiple myeloma. Our providers are subspecialized, focused solely on your specific type of blood cancer. We helped develop many of the current treatments, such as CAR T cell therapy, and we teach others around the world about effective diagnosis and treatment.
The Penn Medicine blood cancer program is one of few programs in the country approved and funded by the National Cancer Institute. In addition, the National Institutes of Health named Penn Medicine’s Abramson Cancer Center one of the original 14 Core Clinical Transplant Centers in the Blood and Marrow Transplant Clinical Network. This national network works to develop and conduct clinical trials to improve patient care.
Rated “exceptional” by The National Cancer Institute
Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our status as a national leader in cancer care is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 7 such centers in the United States. The ACC is also a member of the National Comprehensive Cancer Network, one of a select few cancer centers in the U.S., that are working to promote equitable access to high-quality, advanced cancer care.
Engineering a cure: CAR T cell therapy
Treating disease with cell and gene therapies was once thought to be impossible. CAR T cell therapy, a breakthrough that began at Penn Medicine, uses your own immune cells to fight cancer in a novel way.
Blood cancers we treat
Personalized, leading-edge treatment options
Blood cancer care is changing quickly, with new kinds of treatments being developed all the time. We offer every type of effective treatment for each kind of blood cancer, including the newest classes of treatment—immunotherapy and CAR T cell therapy. We have dedicated care teams that have specific expertise in the different blood cancer treatments we offer, including bone marrow transplant and cell therapy. Your doctor will collaborate with you to identify the best options for your needs, which may include one or more of the following state-of-the-art treatments.
Advancing the future through clinical trials and research
Blood cancer, also called hematological cancer, occurs when abnormal cells in the blood grow out of control. The abnormal cells can crowd out normal blood cells, which have essential functions: Red blood cells help carry oxygen throughout the body, white blood cells help fight infections, and platelets help blood clot.
There are three main blood cancer types—leukemia, lymphoma, and multiple myeloma—that originate from and impact different types of blood cells.
Hematology and oncology experts in Penn Medicine’s Blood Cancer Program have a long history of advancing the science of blood cancers. Our team works diligently to uncover its causes, more accurate methods for diagnosis, and the most effective treatments with the fewest side effects to give patients like you the best possible outcome.
Cancer care at Penn Medicine
Our doctors
Our providers work with you to plan and deliver exceptional treatment and personalized care.
Related articles
CRISPR-based platform pinpoints drivers of leukemia in patient cells
A new toolkit allows researchers to test potential cancer targets directly in patient-leukemia cells.
Delayed toxicities after CAR T cell therapy for myeloma
Research presented at ASH 2025 sheds light on serious side effects that appear weeks or months after CAR T cell therapy for multiple myeloma.
Patient stories
Life, gained: Walter Styer’s CAR T story
Walter Styer’s 11+ life-filled years after being the 10th participant in an early trial, are a testament to the impact of CAR T cell immunotherapy.
How pickleball (and Penn Medicine) saved one patient’s life
With teamwork and determination, specialists at Penn Medicine solved Ronnie Recchia’s life-threatening medical mystery and got him back in the game.
70-year-old bench press competitor tackles rare cancer
While receiving treatment at Penn for a rare cancer, bench press competitor Howard Aaron continued to make fitness an essential part of his life.
‘You won the lottery’: The very first CAR T cell patient
Bill Ludwig will forever be known as the first person successfully treated with a cellular therapy that kills cancer cells with his own immune system.
Improving care for patients with acute lymphocytic leukemia
A clinical trial gave Becky Yu access to treatment that would become the new standard of care for newly diagnosed acute lymphocytic leukemia.
A community hospital is a destination for cancer care
At Lancaster General Health, receiving advanced treatments closer to home has changed the battle with cancer for patients across central Pennsylvania.